Deprescribing proton pump inhibitors Evidence-based clinical practice guideline

被引:3
|
作者
Farrell, Barbara [1 ,2 ,3 ]
Pottie, Kevin [4 ,5 ,6 ]
Thompson, Wade [5 ]
Boghossian, Taline [7 ]
Pizzola, Lisa [6 ]
Rashid, Farah Joy [7 ]
Rojas-Fernandez, Carlos [8 ,9 ]
Walsh, Kate [10 ]
Welch, Vivian [5 ,11 ]
Moayyedi, Paul [12 ]
机构
[1] Univ Ottawa, Dept Family Med, Ottawa, ON, Canada
[2] Univ Waterloo, Sch Pharm, Waterloo, ON, Canada
[3] Univ Ottawa, Bruyere Res Inst, Ottawa, ON, Canada
[4] Univ Ottawa, Dept Family Med, Ottawa, ON, Canada
[5] Univ Ottawa, Sch Epidemiol Publ Hlth & Prevent Med, Ottawa, ON, Canada
[6] Bruyere Res Inst, Ottawa, ON, Canada
[7] Ottawa Hosp, Dept Pharm, Ottawa, ON, Canada
[8] Univ Waterloo, Geriatr Pharmacotherapy, Schlegel UW Res Inst Ageing, Waterloo, ON, Canada
[9] Univ Waterloo, Sch Pharm, Waterloo, ON, Canada
[10] Toronto Cent Community Care Access Ctr, Toronto, ON, Canada
[11] Bruyere Res Inst, Methods Ctr, Ottawa, ON, Canada
[12] McMaster Univ, Div Gastroenterol, Hamilton, ON, Canada
关键词
GASTROESOPHAGEAL-REFLUX DISEASE; PANTOPRAZOLE; 20; MG; MAINTENANCE TREATMENT; LONG-TERM; ON-DEMAND; CONTROLLED TRIAL; PRIMARY-CARE; THERAPY; ESOPHAGITIS; MANAGEMENT;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective To develop an evidence-based guideline to help clinicians make decisions about when and how to safely taper or stop proton pump inhibitors (PPIs); to focus on the highest level of evidence available and seek input from primary care professionals in the guideline development, review, and endorsement processes. Methods Five health professionals (1 family physician, 3 pharmacists, and 1 gastroenterologist) and 5 nonvoting members comprised the overall team; members disclosed conflicts of interest. The guideline process included the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach, with a detailed evidence review in in-person, telephone, and online meetings. Uniquely, the guideline development process included a systematic review of PPI deprescribing trials and examination of reviews of the harm of continued PPI use. Narrative syntheses of patient preferences and resource-implication literature informed recommendations. The team refined guideline content and recommendation wording through consensus and synthesized clinical considerations to address common front-line clinician questions. The draft guideline was distributed to clinicians and then to health care professional associations for review and revisions made at each stage. A decision-support algorithm was developed in conjunction with the guideline. Recommendations This guideline recommends deprescribing PPIs (reducing dose, stopping, or using "on-demand" dosing) in adults who have completed a minimum of 4 weeks of PPI treatment for heartburn or mild to moderate gastroesophageal reflux disease or esophagitis, and whose symptoms are resolved. The recommendations do not apply to those who have or have had Barrett esophagus, severe esophagitis grade C or D, or documented history of bleeding gastrointestinal ulcers. Conclusion This guideline provides practical recommendations for making decisions about when and how to reduce the dose of or stop PPIs. Recommendations are meant to assist with, not dictate, decision making in conjunction with patients.
引用
收藏
页码:354 / 364
页数:11
相关论文
共 50 条
  • [41] Respectful Maternity Care Framework and Evidence-Based Clinical Practice Guideline
    不详
    [J]. JOGNN-JOURNAL OF OBSTETRIC GYNECOLOGIC AND NEONATAL NURSING, 2022, 51 (02): : S7 - S12
  • [42] Prescription of therapeutic exercise in migraine, an evidence-based clinical practice guideline
    La Touche, Roy
    Fierro-Marrero, Jose
    Sanchez-Ruiz, Irene
    de Rivera-Romero, Borja Rodriguez
    Cabrera-Lopez, Carlos Donato
    Lerma-Lara, Sergio
    Requejo-Salinas, Nestor
    de Asis-Fernandez, Francisco
    Elizagaray-Garcia, Ignacio
    Fernandez-Carnero, Josue
    Matesanz-Garcia, Luis
    Pardo-Montero, Joaquin
    Paris-Alemany, Alba
    Reina-Varona, Alvaro
    [J]. JOURNAL OF HEADACHE AND PAIN, 2023, 24 (01):
  • [43] Deprescribing proton pump inhibitors: why, when and how
    Bytzer, Peter
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2018, 209 (10) : 436 - +
  • [44] The Use and Misuse of Proton Pump Inhibitors: An Opportunity for Deprescribing
    Dharmarajan, Thiruvinvamalai S.
    [J]. JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2021, 22 (01) : 15 - 22
  • [45] Deprescribing Strategies: A Prospective Study on Proton Pump Inhibitors
    Calvini, Giulia
    Baiardi, Giammarco
    Mattioli, Francesca
    Milano, Giulia
    Calautti, Francesca
    Zunino, Alessia
    Fraguglia, Carla Elda
    Caccavale, Fabio
    Lantieri, Francesca
    Antonucci, Giancarlo
    [J]. JOURNAL OF CLINICAL MEDICINE, 2023, 12 (08)
  • [46] Deprescribing Proton Pump Inhibitors: Quality Improvement Project
    Fernandez, Wilfor J. Diaz
    Forget, Nickole
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S623 - S624
  • [47] Patient and Provider Perspectives on Deprescribing Proton Pump Inhibitors
    Ikeji, Chisom
    Williams, Anne
    Hennawi, George
    Brandt, Nicole J.
    [J]. JOURNAL OF GERONTOLOGICAL NURSING, 2019, 45 (10): : 9 - 17
  • [48] The effects of diuretic deprescribing in adult patients: A systematic review to inform an evidence-based diuretic deprescribing guideline
    van Poelgeest, Eveline
    Paoletti, Luca
    Ozkok, Serdar
    Pinar, Ezgi
    Bahat, Guelistan
    Vuong, Vincent
    Topinkova, Eva
    Daams, Joost
    McCarthy, Lisa
    Thompson, Wade
    van Der Velde, Nathalie
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024,
  • [49] Evidence-based Practice Guideline for the Treatment of CKD
    [J]. Clinical and Experimental Nephrology, 2009, 13 : 537 - 566